Management of a 35-Year-Old Woman on Ruxolitinib
This patient requires tuberculosis screening before starting ruxolitinib, appropriate vaccinations, regular CBC and metabolic monitoring every 2-4 weeks until stable, lipid monitoring at 8-12 weeks, and vigilant infection surveillance throughout treatment. 1
Prophylactic Measures and Additional Medications
Infection Screening and Prophylaxis
Tuberculosis evaluation is mandatory before initiating ruxolitinib. Patients must be assessed for TB risk factors, and those at higher risk should be tested for latent infection. If evidence of active or latent TB exists, consultation with a TB specialist is required prior to starting ruxolitinib 1. This is critical because TB infection has been reported in patients receiving ruxolitinib, including disseminated forms that can mimic metastatic disease 2, 3.
Hepatitis B screening is essential. Patients with chronic HBV infection can experience increases in HBV-DNA titer with or without elevated liver enzymes while on ruxolitinib 1. Active HBV should be treated before starting therapy.
Vaccinations should be administered per NCCN Guidelines for Prevention and Treatment of Cancer-Related Infections before starting immunosuppressive therapy 1. Live vaccines should be avoided once treatment begins.
Monitoring Requirements
CBC and comprehensive metabolic panel (including uric acid and LDH) must be performed:
- Before initiating therapy
- Every 2-4 weeks until doses are stabilized
- Then as clinically indicated 1
Lipid monitoring is required approximately 8-12 weeks after starting ruxolitinib, as the drug is associated with increases in total cholesterol, LDL cholesterol, and triglycerides. Manage according to clinical guidelines for hyperlipidemia 1.
Cardiovascular Risk Management
Baseline and ongoing counseling for cardiovascular risk factor modification is recommended, including assessment of smoking, diet, exercise, and thrombotic/hemorrhagic risk factors 1. Given that ruxolitinib was associated with lower thromboembolic event rates in clinical trials (1.8% vs 8.2% with best available therapy) 4, maintaining cardiovascular health remains important.
Side Effects and Management
Hematologic Toxicities
Cytopenias are the most common hematologic adverse effects:
- Thrombocytopenia: Manage by dose reduction or interruption based on clinical parameters. Platelet transfusions may be necessary 1
- Anemia: May require blood transfusions and/or dose modifications. Grade 3/4 anemia occurred in 2% of ruxolitinib-treated patients in the RESPONSE trial 4
- Neutropenia: Severe neutropenia (ANC <0.5 × 10⁹/L) is generally reversible by withholding ruxolitinib 1
For recurrent infections in neutropenic patients, consider G-CSF or GM-CSF per NCCN infection guidelines 1.
Infectious Complications
Ruxolitinib increases risk of opportunistic infections. Patients should be carefully observed for signs and symptoms of infection, and appropriate treatment should be initiated promptly 1.
Herpes zoster infection is notably increased: 6% incidence in ruxolitinib-treated patients versus 0% with standard therapy in the RESPONSE trial 4. The rate was 5.3-5.4 per 100 patient-years with extended follow-up 5. Consider antiviral prophylaxis, particularly in high-risk patients.
Bacterial infections are common, especially bacteremia in patients with acute conditions 6. Maintain high clinical suspicion and low threshold for empiric antibiotics.
Non-Hematologic Side Effects
Common non-hematologic adverse events include headache, diarrhea, pruritus, and fatigue 7.
Withdrawal syndrome: Abrupt discontinuation can provoke a shock-like syndrome due to re-emergence of suppressed inflammatory cytokines 8. When discontinuing ruxolitinib for reasons other than thrombocytopenia or neutropenia, taper the dose gradually rather than stopping abruptly 1.
Special Considerations for Women of Childbearing Age
At 35 years old, contraception counseling is important. Hydroxyurea is contraindicated in pregnancy and breastfeeding 4. If this patient were to become pregnant, she would need to switch to interferons (interferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b) for cytoreductive therapy 4.
Clinical Pitfalls to Avoid
False-negative TB testing: Ruxolitinib-induced immunosuppression can lead to false-negative interferon-γ release assay results 2. Maintain high clinical suspicion even with negative screening.
Tumor marker elevation: Several tumor markers (soluble IL-2 receptor, NSE, CA125, CA15-3) can be elevated in tuberculosis, potentially mimicking malignancy 2. Consider TB in the differential when imaging shows concerning lesions.
Inadequate monitoring: The every 2-4 week CBC monitoring is not optional—it's essential for detecting cytopenias before they become severe 1.
Abrupt discontinuation: Always taper unless stopping for severe cytopenias 1.